ELECTRONIC SUPPLEMENTARY MATERIALS
Title
Prospective observational study of treatment pattern, effectiveness and safety of
zoledronic acid therapy beyond 24 months in patients with multiple myeloma or bone
metastases from solid tumors.
Support Care Cancer
Authors
T. Van den Wyngaert, M. Delforge, C. Doyen, L. Duck, K. Wouters, I. Delabaye,
C. Wouters, H. Wildiers.
Corresponding author
Name:
Dr. Tim Van den Wyngaert
E-mail:
tim.van.den.wyngaert@uza.be
Address:
Antwerp University Hospital
Department of Nuclear Medicine
Wilrijkstraat 10
2650 Edegem
Belgium
1
FIGURE S1. Mean exposure to zoledronic acid relative to the recommended dose as
calculated per 3 month observation period for patients with solid tumors and multiple
myeloma who completed the 18 month follow-up (n=218).
2
FIGURE S2. Kaplan-Meier estimates of the proportion of patients without an SRE
during the planned 18-month follow-up period by primary malignancy and regardless
of study completion (log-rank p=0.03).
3
FIGURE S3. Trending of the incidence of the 43 adverse event (AE) types with at
least 5 occurrences. These AEs account for 55% of all reported AEs on a total of 226
unique AE types. The linear slope parameter of the incidence of each AE was
calculated over 6 month intervals during the 18 month follow-up. Corresponding 95%
confidence intervals and the Cochran-Armitage p-values for trend are shown,
together with the overall AE prevalence respective to the 298 study patients. A
significant positive/negative slope parameter indicates an increase/decrease in AE
incidence during the study, respectively.
4
TABLE S1. Zoledronic acid treatment decisions at each visit in patients completing
18 months of follow-up (n=218).
Decision
Continued
Discontinued
Interrupted
Re-initiated
Number of patients per study month (%)
3
6
9
12
15
18
194 (89.0) 185 (84.9) 172 (78.9) 162 (74.3) 149 (68.3) 134 (61.5)
18 (8.3)
7 (3.2)
12 (5.5)
12 (5.5)
11 (5.0)
14 (6.4)
6 (2.8)
4 (1.8)
7 (3.2)
4 (1.8)
5 (2.3)
4 (1.8)
0 (0.0)
2 (0.9)
2 (0.9)
3 (1.4)
3 (1.4)
5 (2.3)
5